Loading...
OTCMTHMO
Market cap9kUSD
Dec 20, Last price  
0.00USD
1D
20.00%
1Q
-99.66%
Jan 2017
-100.00%
Name

Cesca Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:THMO chart
P/E
P/S
0.00
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
125.20%
Rev. gr., 5y
-0.47%
Revenues
9m
-9.90%
10,177,00012,048,00016,751,00021,946,00019,799,00023,088,00023,400,00019,023,00017,963,00015,987,00016,042,00011,929,00014,525,00012,026,0009,672,00013,047,0009,744,0009,294,00010,483,0009,445,000
Net income
-18m
L+59.49%
-8,220,000-6,142,000-6,776,000-9,181,000-8,550,000-5,193,000-2,567,000-4,986,000-3,086,000-8,631,000-14,852,000-18,588,000-29,095,000-4,566,000-39,716,000-9,497,000-16,351,000-11,379,000-11,270,000-17,975,000
CFO
-4m
L-48.91%
-7,931,000-2,998,000-7,762,000-8,451,000-8,796,000-4,428,000-2,092,000-3,885,000-3,082,000-7,836,000-10,649,000-9,625,000-7,215,000-3,317,000-6,983,000-3,260,000-14,393,000-6,620,000-7,283,000-3,721,000
Earnings
Apr 14, 2025

Profile

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
IPO date
Jun 05, 1987
Employees
40
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑062016‑062015‑06
Income
Revenues
9,445
-9.90%
10,483
12.79%
9,294
-4.62%
Cost of revenue
8,798
9,432
8,010
Unusual Expense (Income)
NOPBT
647
1,051
1,284
NOPBT Margin
6.85%
10.03%
13.82%
Operating Taxes
5,071
6,404
Tax Rate
482.49%
498.75%
NOPAT
647
(4,020)
(5,120)
Net income
(17,975)
59.49%
(11,270)
-0.96%
(11,379)
-30.41%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,857
4,583
6,832
BB yield
-200.74%
-259.93%
-2,580.50%
Debt
Debt current
7,656
6,739
813
Long-term debt
8,700
7,252
10,041
Deferred revenue
127
911
1,244
Other long-term liabilities
(2,873)
17
20
Net debt
14,356
9,814
3,574
Cash flow
Cash from operating activities
(3,721)
(7,283)
(6,620)
CAPEX
(1,733)
(400)
(93)
Cash from investing activities
(1,733)
(400)
(93)
Cash from financing activities
3,278
4,586
6,832
FCF
1,964
(7,152)
(4,506)
Balance
Cash
2,000
4,177
7,280
Long term investments
Excess cash
1,528
3,653
6,815
Stockholders' equity
(285,967)
(267,054)
(265,050)
Invested Capital
295,993
281,670
280,167
ROIC
0.22%
ROCE
9.08%
7.19%
8.49%
EV
Common stock shares outstanding
2,368
551
262
Price
0.60
-81.22%
3.20
216.83%
1.01
-51.67%
Market cap
1,423
-19.28%
1,763
565.96%
265
-9.20%
EV
13,862
10,604
3,408
EBITDA
1,794
1,977
1,917
EV/EBITDA
7.73
5.36
1.78
Interest
10,032
5,616
6,103
Interest/NOPBT
1,550.54%
534.35%
475.31%